STEREOTACTIC RADIOTHERAPY FOR LUNG CANCER USING ACTIVE BREATHING CONTROL SYSTEM
-
- TAKAI Kenji
- Department of Therapeutic Radiology, Tohoku University Hospital
-
- TAKAI Yoshihiro
- Course of Health Sciences, Tohoku University School of Medicine
-
- KOTO Masashi
- Department of Therapeutic Radiology, Tohoku University Hospital
-
- MITSUYA Masatoshi
- Department of Clinical Radiology, Tohoku University Hospital
-
- TAKEDA Ken
- Department of Radiology, Sendai Medical Center
-
- NEMOTO Kenji
- Department of Therapeutic Radiology, Tohoku University Hospital
-
- OGAWA Yoshihiro
- Department of Therapeutic Radiology, Tohoku University Hospital
-
- SAKAYAUCHI Tohru
- Department of Therapeutic Radiology, Tohoku University Hospital
-
- SUGAWARA Toshiyuki
- Department of Therapeutic Radiology, Tohoku University Hospital
-
- YAMADA Shogo
- Department of Therapeutic Radiology, Tohoku University Hospital
Bibliographic Information
- Other Title
-
- 能動的呼吸制御装置を用いた肺癌定位放射線治療
Search this article
Abstract
In Tohoku University Hospital, primary or metastatic lung cancers with the respiratory motion of more than 1 cm were treated with SRT (stereotactic radiotherapy) under ABC (active breathing control: ABC-SRT). The local control rate and lung toxicity treated with ABC-SRT were analyzed. The indication of ABC-SRT is as follows: tumor size in largest diameter ≤5 cm, motion distance ≥1 cm, and patient’s consent to treatment.<br>Nineteen patients (average age: 58.2 years, male 12: female 7) with 25 lesions were enrolled to ABC-SRT during March 2000 and July 2004. Patients with primary lung cancer were four, the others with metastatic cancer. Prescribed doses were 45 Gy/3 fr or 60 Gy/8 fr at the isocenter. ABC-SRT was successfully done for all patients except one patient who failed to be given the prescribed dose (only 45 Gy/6 fr were administered). In 24 lesions with complete treatment, the control rate in 1/2/4 years was 94.1%/74.0%/74.0%, respectively. In tumors <2.5 cm size in largest diameter, the control rate was 90.0%, ≥2.5 cm, 42.9%, tendency of significance (p=0.0579) was observed. One patient developed grade 2 pneumonitis (RTOG: Radiation Therapy Oncologic Group/EORTC: European Organization for Research and Treatment of Cancer), who was then orally medicated with steroid to cure. The others developed grade 0-1 pneumonitis. Although 10 of 19 patients were treated with chemotherapy, the lung toxicity was relatively light. Reduction of PTV by ABC seem to reduce the lung toxicity. In tumors <2.5 cm size in largest diameter, good control rate was acquired compared to the tumors ≥2.5 cm in size. We’re going to analyze the lung toxicity treated without ABC-SRT to compare the present results. [Article in Japanese]
Journal
-
- The Journal of JASTRO
-
The Journal of JASTRO 18 (2), 91-98, 2006
Japanese Society for Therapeutic Radiology and Oncology
- Tweet
Details 詳細情報について
-
- CRID
- 1390282679308672512
-
- NII Article ID
- 10021282137
- 130004497097
-
- NII Book ID
- AN10123988
-
- ISSN
- 18819885
- 10409564
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- CiNii Articles
- KAKEN
-
- Abstract License Flag
- Disallowed